Skip to main content

Advertisement

SpringerLink
Log in

Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease

  • Multicenter Seminars: IBD (MUSE: IBD)
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology. 1995;45:416–421. https://doi.org/10.1212/wnl.45.3.416.

    Article  CAS  PubMed  Google Scholar 

  2. Dolapcioglu C, Guleryuzlu Y, Uygur-Bayramicli O, Ahishali E, Dabak R. Asymptomatic brain lesions on cranial magnetic resonance imaging in inflammatory bowel disease. Gut Liver. 2013;7:169–174. https://doi.org/10.5009/gnl.2013.7.2.169.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000;75:802–806. https://doi.org/10.4065/75.8.802.

    Article  CAS  PubMed  Google Scholar 

  4. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129:819–826. https://doi.org/10.1053/j.gastro.2005.06.022.

    Article  PubMed  Google Scholar 

  5. Ferro JM, Oliveira SN, Correia L. Neurologic manifestations of inflammatory bowel diseases. Handb Clin Neurol. 2014;120:595–605. https://doi.org/10.1016/B978-0-7020-4087-0.00040-1.

    Article  PubMed  Google Scholar 

  6. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2.

    Article  PubMed  Google Scholar 

  7. Solomon AJ, Naismith RT, Cross AH. Misdiagnosis of multiple sclerosis: impact of the 2017 McDonald criteria on clinical practice. Neurology. 2019;92:26–33. https://doi.org/10.1212/WNL.0000000000006583.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Geissler A, Andus T, Roth M, et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet Lond Engl. 1995;345:897–898. https://doi.org/10.1016/s0140-6736(95)90013-6.

    Article  CAS  Google Scholar 

  9. Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJF. Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know! Mult Scler Houndmills Basingstoke Engl. 2013;19:259–265. https://doi.org/10.1177/1352458512461393.

    Article  Google Scholar 

  10. Zikou AK, Kosmidou M, Astrakas LG, Tzarouchi LC, Tsianos E, Argyropoulou MI. Brain involvement in patients with inflammatory bowel disease: a voxel-based morphometry and diffusion tensor imaging study. Eur Radiol. 2014;24:2499–2506. https://doi.org/10.1007/s00330-014-3242-6.

    Article  PubMed  Google Scholar 

  11. Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:382–393.e1. https://doi.org/10.1016/j.cgh.2013.08.023(quiz e22).

    Article  Google Scholar 

  12. Kohoutova D, Moravkova P, Kruzliak P, Bures J. Thromboembolic complications in inflammatory bowel disease. J Thromb Thrombolysis. 2015;39:489–498. https://doi.org/10.1007/s11239-014-1129-7.

    Article  CAS  PubMed  Google Scholar 

  13. Kosmidou M, Katsanos AH, Katsanos KH, et al. Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis. J Neurol. 2017;264:254–259. https://doi.org/10.1007/s00415-016-8340-8.

    Article  CAS  PubMed  Google Scholar 

  14. Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain J Neurol. 2018;141:1900–1916. https://doi.org/10.1093/brain/awy131.

    Article  Google Scholar 

  15. Buscarinu MC, Romano S, Mechelli R, et al. Intestinal permeability in relapsing-remitting multiple sclerosis. Neurother J Am Soc Exp Neurother. 2018;15:68–74. https://doi.org/10.1007/s13311-017-0582-3.

    Article  CAS  Google Scholar 

  16. Kim D, Zeng MY, Núñez G. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. Exp Mol Med. 2017;49:e339. https://doi.org/10.1038/emm.2017.24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Forbes JD, Chen C-Y, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 2018;6:221. https://doi.org/10.1186/s40168-018-0603-4.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol Orlando Fla. 2012;142:2–8. https://doi.org/10.1016/j.clim.2011.03.004.

    Article  CAS  Google Scholar 

  19. Lin CH, Kadakia S, Frieri M. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmun Rev. 2014;13:114–116. https://doi.org/10.1016/j.autrev.2013.09.011.

    Article  CAS  PubMed  Google Scholar 

  20. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47:1531–1534. https://doi.org/10.1212/wnl.47.6.1531.

    Article  PubMed  Google Scholar 

  21. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53:457–465.

  22. Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36. https://doi.org/10.1007/s11910-017-0742-1.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Colombel J-F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2003;. https://doi.org/10.1053/j.gastro.2003.10.047.

    Article  PubMed  Google Scholar 

  24. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado M-J, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188–193. https://doi.org/10.1016/j.autrev.2009.10.003.

    Article  CAS  PubMed  Google Scholar 

  25. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13:54–58. https://doi.org/10.1016/j.autrev.2013.09.002.

    Article  CAS  PubMed  Google Scholar 

  26. D’Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212. https://doi.org/10.1038/ajg.2010.392(quiz 213).

    Article  PubMed  Google Scholar 

  27. Ghosh S. Biologic therapies: lessons from multiple sclerosis. Dig Dis Basel Switz. 2012;30:383–386. https://doi.org/10.1159/000338131.

    Article  Google Scholar 

  28. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796–804. https://doi.org/10.1016/S1474-4422(08)70173-X.

    Article  CAS  PubMed  Google Scholar 

  29. Dubeau M-F, Iacucci M, Beck PL, et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis. 2013;19:445–456. https://doi.org/10.1002/ibd.22990.

    Article  PubMed  Google Scholar 

  30. Eckmann JD, Chedid V, Quinn KP, Bonthu N, Nehra V, Raffals LE. De Novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18:252–253. https://doi.org/10.1016/j.cgh.2019.03.027.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Ave, S-357, San Francisco, CA, 94143-0451, USA

    Emilie H. Regner, Jared L. Bain, Michael G. Kattah & Uma Mahadevan

  2. Division of Neuroimmunology and Glial Biology, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA

    Ari J. Green

  3. Department of Ophthalmology, University of California, San Francisco, CA, USA

    Ari J. Green

Authors
  1. Emilie H. Regner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ari J. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jared L. Bain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael G. Kattah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uma Mahadevan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uma Mahadevan.

Ethics declarations

Conflict of interest

Uma Mahadevan—Consultant: Abbvie, Janssen, Gilead, BMS, Takeda; Research: Pfizer, Genentech.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Regner, E.H., Green, A.J., Bain, J.L. et al. Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease. Dig Dis Sci 65, 2527–2532 (2020). https://doi.org/10.1007/s10620-020-06449-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06449-2

Search

Navigation